Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa2001017
10.1056/nejmoa2001017 · External reference
10.1002/jmv.25681
10.1002/jmv.25681 · External reference
10.1038/s41467-019-10280-3
10.1038/s41467-019-10280-3 · External reference
One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities
10.1073/pnas.1323705111 · 2014 · External reference
Unresolved reference
External reference
SARS-CoV-2 RNA-dependent RNA polymerase as a target for high-throughput drug screening
2023 · External reference
Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against RNA-Dependent RNA Polymerase Complex (nsp7/nsp8/nsp12) of SARS-CoV-2
2021 · External reference
10.1016/j.bbrc.2020.10.091
10.1016/j.bbrc.2020.10.091 · External reference
10.3390/jcm9041131
10.3390/jcm9041131 · External reference
10.1177/2472555220942123
10.1177/2472555220942123 · External reference
10.1016/j.ijbiomac.2021.03.112
10.1016/j.ijbiomac.2021.03.112 · External reference
Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation
2016 · External reference
10.1074/jbc.m709563200
10.1074/jbc.m709563200 · External reference
Within and beyond the nucleotide addition cycle of viral RNA-dependent RNA polymerases
10.3389/fmolb.2021.822218 · 2022 · External reference
10.1038/s41586-022-05664-3
10.1038/s41586-022-05664-3 · External reference
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
10.1073/pnas.2021946118 · 2021 · External reference
10.1038/s41467-022-28113-1
10.1038/s41467-022-28113-1 · External reference
10.1016/j.xinn.2021.100080
10.1016/j.xinn.2021.100080 · External reference
10.1016/j.molcel.2021.01.035
10.1016/j.molcel.2021.01.035 · External reference
10.1126/science.abc1560
10.1126/science.abc1560 · External reference
10.1016/j.jbc.2021.101529
10.1016/j.jbc.2021.101529 · External reference
10.1074/jbc.ac120.015720
10.1074/jbc.ac120.015720 · External reference
10.1038/s41467-020-20542-0
10.1038/s41467-020-20542-0 · External reference
10.1016/j.cell.2020.05.034
10.1016/j.cell.2020.05.034 · External reference
Mechanisms of inhibition of viral RNA replication by nucleotide analogs
10.1016/bs.enz.2021.07.001 · 2021 · External reference
10.1002/jmv.26264
10.1002/jmv.26264 · External reference
10.1016/j.bbrc.2020.08.116
10.1016/j.bbrc.2020.08.116 · External reference
10.1038/s41586-020-2423-5
10.1038/s41586-020-2423-5 · External reference
10.1093/jac/dkaa239
10.1093/jac/dkaa239 · External reference
Remdesivir for the treatment of Covid-19-preliminary report
2020 · External reference
10.1038/s41422-020-0282-0
10.1038/s41422-020-0282-0 · External reference
10.1038/s41586-022-04482-x
10.1038/s41586-022-04482-x · External reference
10.1016/j.antiviral.2021.105078
10.1016/j.antiviral.2021.105078 · External reference
10.1126/scitranslmed.abm3410
10.1126/scitranslmed.abm3410 · External reference
10.1016/j.antiviral.2020.104857
10.1016/j.antiviral.2020.104857 · External reference
Co-administration of favipiravir and the remdesivir Metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the syrian hamster model
10.1128/mbio.03044-21 · 2022 · External reference
10.1128/aac.00222-22
10.1128/aac.00222-22 · External reference
Identifying small-molecule inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase by establishing a fluorometric assay
10.3389/fimmu.2022.844749 · 2022 · External reference
Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-Dependent RNA polymerase
2021 · External reference
10.1074/jbc.ra120.013679
10.1074/jbc.ra120.013679 · External reference
10.1074/jbc.ac120.013056
10.1074/jbc.ac120.013056 · External reference
10.1016/j.isci.2020.101849
10.1016/j.isci.2020.101849 · External reference
10.7554/elife.70968
10.7554/elife.70968 · External reference
10.1021/acs.jpclett.2c00087
10.1021/acs.jpclett.2c00087 · External reference
10.1021/acs.jpcb.0c04198
10.1021/acs.jpcb.0c04198 · External reference
10.1021/acs.jcim.0c01277
10.1021/acs.jcim.0c01277 · External reference
Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study
10.1016/j.lfs.2020.117592 · 2020 · External reference
10.1007/s11030-021-10215-5
10.1007/s11030-021-10215-5 · External reference
A systematic study on the optimal nucleotide analogue concentration and rate limiting nucleotide of the SARS-CoV-2 RNA-Dependent RNA polymerase
10.3390/ijms23158302 · 2022 · External reference
10.1016/j.celrep.2021.109882
10.1016/j.celrep.2021.109882 · External reference
AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19
2021 · External reference
10.1039/d1cp03049c
10.1039/d1cp03049c · External reference
10.1021/acs.jproteome.0c00392
10.1021/acs.jproteome.0c00392 · External reference
10.1093/jac/dkab072
10.1093/jac/dkab072 · 2020 · External reference
10.1038/s41467-020-19055-7
10.1038/s41467-020-19055-7 · External reference
Characterization of SARS-CoV-2 replication complex elongation and proofreading activity
10.1038/s41598-022-13380-1 · 2022 · External reference
10.1111/febs.16587
10.1111/febs.16587 · External reference
Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication
10.1021/acsomega.1c05998 · 2022 · External reference
Cordycepin as a promising inhibitor of SARS-CoV-2 RNA dependent RNA polymerase (RdRp)
10.2174/0929867328666210820114025 · 2022 · External reference
10.1101/2020.04.03.022939
10.1101/2020.04.03.022939 · External reference
10.3390/molecules27134212
10.3390/molecules27134212 · External reference
Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease
10.1021/acsomega.1c07095 · 2022 · External reference
RepurposinG Didanosine as A Potential Treatment for COVID-19 using single-Cell RNA sequencing data
10.1128/msystems.00297-20 · 2020 · External reference
10.1080/07391102.2021.2000498
10.1080/07391102.2021.2000498 · External reference
Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant
10.1016/j.compbiolchem.2022.107768 · 2022 · External reference
Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties
10.1172/jci.insight.153165 · 2022 · External reference
10.1038/s41594-021-00651-0
10.1038/s41594-021-00651-0 · External reference
10.1016/j.jbc.2021.100770
10.1016/j.jbc.2021.100770 · External reference
10.1126/scitranslmed.abb5883
10.1126/scitranslmed.abb5883 · External reference
10.1016/j.isci.2022.104293
10.1016/j.isci.2022.104293 · External reference
Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture
10.1038/s42003-022-03101-9 · 2022 · External reference
10.1038/s41467-021-22580-8
10.1038/s41467-021-22580-8 · External reference
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
10.1172/jci.insight.160108 · 2022 · External reference
10.1038/s41467-020-18463-z
10.1038/s41467-020-18463-z · External reference
10.1126/scitranslmed.abo0718
10.1126/scitranslmed.abo0718 · External reference
10.1039/d1me00088h
10.1039/d1me00088h · External reference
10.1039/d0cp05948j
10.1039/d0cp05948j · External reference
10.1021/acs.biochem.2c00341
10.1021/acs.biochem.2c00341 · External reference
10.1021/acs.jcim.2c00201
10.1021/acs.jcim.2c00201 · External reference
Translocation pause of remdesivir-containing primer/template RNA duplex within SARS-CoV-2's RNA polymerase complexes
10.3389/fmolb.2022.999291 · 2022 · External reference
10.1016/j.checat.2022.03.019
10.1016/j.checat.2022.03.019 · External reference
Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin
10.1074/jbc.c100349200 · 2001 · External reference
10.1021/acs.jpclett.2c01314
10.1021/acs.jpclett.2c01314 · External reference
Alternative role of Motif B in template dependent polymerase inhibition
10.1063/1674-0068/cjcp2203053 · 2022 · External reference
10.1093/infdis/jiab247
10.1093/infdis/jiab247 · External reference
10.1128/jvi.02346-12
10.1128/jvi.02346-12 · External reference
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) ribofuranosyl 5 '-Triphosphate towards influenza a virus polymerase
10.1371/journal.pone.0068347 · 2013 · External reference
Favipiravir elicits antiviral mutagenesis during virus replication in vivo
10.7554/elife.03679 · 2014 · External reference
Distinct effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis
10.1128/aac.01156-16 · 2016 · External reference
Favipiravir and severe acute respiratory syndrome coronavirus 2 in hamster model
2020 · External reference
Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
2020 · External reference
10.3390/v15020544
10.3390/v15020544 · External reference
10.1126/science.abj5508
10.1126/science.abj5508 · External reference
10.1093/jac/dkaa444
10.1093/jac/dkaa444 · External reference
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
2023 · External reference
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
2021 · External reference
10.1016/j.bbrc.2022.07.087
10.1016/j.bbrc.2022.07.087 · External reference
A series of adenosine analogs as the first efficacious anti-SARS-CoV-2 drugs against the B.1.1.529.4 lineage: a preclinical repurposing research study
10.1002/slct.202201912 · 2022 · External reference
10.3390/v14081790
10.3390/v14081790 · External reference
10.1093/nar/gkac1177
10.1093/nar/gkac1177 · External reference
10.1126/science.abi9310
10.1126/science.abi9310 · External reference
10.1016/j.virusres.2006.01.017
10.1016/j.virusres.2006.01.017 · External reference
10.1016/j.molcel.2020.07.027
10.1016/j.molcel.2020.07.027 · External reference
The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2
10.1128/jvi.01246-20 · 2020 · External reference
10.1093/nar/gkab1303
10.1093/nar/gkab1303 · External reference
10.1016/j.jmb.2023.167973
10.1016/j.jmb.2023.167973 · External reference
Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex
10.1073/pnas.2102516118 · 2021 · External reference
Ensemble cryo-EM reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication-transcription complex
10.1038/s41594-022-00734-6 · 2022 · External reference
10.3390/v14071413
10.3390/v14071413 · External reference
Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN
10.1073/pnas.2106379119 · 2022 · External reference
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir
10.1038/s41598-020-73641-9 · 2020 · External reference
10.1016/j.cell.2021.05.033
10.1016/j.cell.2021.05.033 · External reference
Combining SARS-CoV-2 proofreading exonuclease and RNA-Dependent RNA polymerase inhibitors as a strategy to combat COVID-19: a high-throughput in silico screening
10.3389/fmicb.2021.647693 · 2021 · External reference
